Results 61 to 70 of about 2,141 (187)

Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by Age [PDF]

BACKGROUND: Abrocitinib has a manageable long-term safety profile for patients with moderate-to-severe atopic dermatitis. Identifying populations at higher risk of adverse events will help optimize dose selection.
Valdez, Hernan, Silverberg, Jonathan I, Geng, Bob, Romero, William, Irvine, Alan D, Simpson, Eric L, Alderfer, Justine, Deleuran, Mette, Cork, Michael J, Fan, Haiyun, Stein Gold, Linda F   +10 more
core   +3 more sources

New Insights Into Immunomodulatory Strategies for Drug Hypersensitivity Reactions: An EAACI Task Force Report

Clinical and Translational Allergy, Volume 16, Issue 8, August 2026.
ABSTRACT Drug hypersensitivity reactions (DHRs) are a global health concern and remain challenging to investigate owing to the heterogeneity of endotypes and phenotypes, as well as the lack of standardized biomarkers. Until recently, strict drug avoidance was the only management strategy for severe DHRs.
Ana Maria Copaescu, Valentina Gueli, Jitesh Chahuan, Waad Albalawi, Giovanna Sfriso, Mattia Giovannini, Leticia de las Vecillas, Aspasia Karavelia, Marina Labella, Ruben Fernandez‐Santamaria, Francesca Mori, Lene H. Garvey, Patrizia Bonadonna, Maria Jose Torres   +13 more
wiley   +1 more source

Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis

Dermatology and Therapy
Introduction Early prediction of abrocitinib efficacy in atopic dermatitis (AD) could help identify candidates for an early dose increase. A predictive model determined week 12 efficacy based on week 4 responses in patients receiving abrocitinib 100 mg ...
April W. Armstrong, Andrew F. Alexis, Andrew Blauvelt, Jonathan I. Silverberg, Claire Feeney, Mark Levenberg, Gary Chan, Fan Zhang, Luke Fostvedt   +8 more
doaj   +1 more source

Successful treatment of eosinophilic esophagitis with upadacitinib prescribed for atopic dermatitis

JPGN Reports, Volume 7, Issue 3, Page 449-451, August 2026.
Abstract We describe a pediatric patient treated with upadacitinib for atopic dermatitis (AD) who subsequently achieved sustained clinical and histologic remission of eosinophilic esophagitis (EoE). Upadacitinib is an oral small molecule selective Janus kinase 1 inhibitor that inhibits janus kinase‐signal transduction and activation of transcription ...
Nathalie Nguyen, Maureen Bauer
wiley   +1 more source

Abrocitinib Treatment for Localized Type of Generalized Pustular Psoriasis: A Case Report [PDF]

Zhili Yang, Jiejie Lu, Zhen Li Department of Dermatology, The Fifth People’s Hospital of Hainan Province, Haikou, Hainan, People’s Republic of ChinaCorrespondence: Zhen Li, Email nanji9207@163.com Jiejie Lu, Email lujiejie677@163.comAbstract: Generalized
Yang Z, Li Z, Lu J
core  

S3‐Leitlinie Diagnostik und Therapie der Alopecia areata – Teil 2: Therapie, psychosoziale und kosmetische Unterstützung

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 8, Page 1155-1179, August 2026.
Zusammenfassung In diesem zweiten Teil der S3‐Leitlinie zur Diagnostik und Therapie der Alopecia areata (AA) stellen wir die zentralen Inhalte und Empfehlungen zur topischen und systemischen Therapie, zur Lebensqualität und zu Unterstützungsangeboten vor.
Ulrike Blume‐Peytavi, Andria Constantinou, Tsenka Tomova‐Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens, Kerstin Zienert, Claudia Stenders, Ricardo Niklas Werner, Doris Wilborn   +13 more
wiley   +1 more source

Abrocitinib Monotherapy for Refractory Prurigo Nodularis: Report of Two Successful Cases [PDF]

Jingyao Liang,1,2,* Wei Li,1,2,* Wenyan Liu,1,2 Yihui Yu,1,2 Hui Ye,1,2 Xibao Zhang1,2 1Institute of Dermatology, Guangzhou Medical University, Guangzhou, Guangdong, 510095, People’s Republic of China; 2Department of Dermatology, Guangzhou ...
Li W, Liang J, Zhang X, Ye H, Liu W, Yu Y   +5 more
core  

Selective JAK inhibitor: Abrocitinib (JAK1-Selective)

Değer Dil Düzenle The JAK signaling pathway has a critical role in the pathogenesis of various chronic inflammatory diseases, such as atopic dermatitis.
Şeker, Ümmühan, Aydoğan, Kenan
core   +1 more source

Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry

Acta Dermato-Venereologica
Limited daily practice data on the effect of abrocitinib in patients with atopic dermatitis are available. The aim of this multicentre prospective study is to evaluate the effectiveness and safety of abrocitinib in patients with atopic dermatitis treated
Esmé Kamphuis, Celeste M. Boesjes, Laura Loman, Marijke Kamsteeg, Inge Haeck, Anneke M.T. van Lynden-van Nes, Klaziena Politiek, Liana F. van der Gang, Marlies de Graaf, Marjolein S. de Bruin-Weller, Marie L.A. Schuttelaar   +10 more
doaj   +1 more source

Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE

Dermatology and Therapy
Introduction Primary results of the JADE DARE trial (NCT04345367) demonstrated that abrocitinib was superior to dupilumab in reducing the signs and symptoms of moderate-to-severe atopic dermatitis (AD).
Jonathan I. Silverberg, Eric L. Simpson, Andrew E. Pink, Stephan Weidinger, Gary Chan, Pinaki Biswas, Claire Clibborn, Erman Güler   +7 more
doaj   +1 more source